Study of Safety and Efficacy of the Percutaneous Reduction of Mitral Valve Regurgitation in Heart Failure Patients

Inclusion Criteria: * Functional MR 2+ - 4+ * Symptomatic heart failure, NYHA Class II to IV * LVEF \> 25% or \< 50% OR dilated mitral annulus \> 30mm Exclusion Criteria: * MR of organic origin * Severe mitral leaflet tethering * History of MI or PCI within 60 days of study procedure * Inability to walk a minimum of 100 meters in 6 minutes * Significant left main stenosis or proximal circumflex stent * Indication of non-patent CSO or discontinuous CS-GCV-AIV * Bi-ventricular with leads in CS or other devices impeding device placement * Severe aortic valvular disease * Chronic corticosteroid use other than \< 20mg prednisone for arthritis * Significant co-morbidities